{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:00:01Z","timestamp":1763017201513},"reference-count":0,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[1994,3,1]],"date-time":"1994-03-01T00:00:00Z","timestamp":762480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1994,3]]},"abstract":"<jats:p>The purpose of the study reported here was to investigate the impact of prophylaxis against gram-positive infections in patients undergoing high-dose chemotherapy and autologous bone marrow transplantation in a randomized trial. Forty-three patients undergoing high-dose chemotherapy with autologous bone marrow transplant were enrolled in a nonblinded randomized trial to receive or not to receive prophylaxis for gram-positive infections with 10(6) U of penicillin intravenously (i.v.) every 6 h (q6h) (if penicillin allergic, 750 mg of vancomycin i.v. q12h) in addition to standard antimicrobial prophylaxis with 400 mg of norfloxacin orally three times a day, 200 mg of fluconazole orally once a day, and 5 mg of acyclovir per kg of body weight i.v. q12h. The patients were being treated for germ cell cancer (n = 15), breast cancer (n = 16), Hodgkin's disease (n = 3), non-Hodgkin's lymphoma (n = 4), acute myeloid leukemia (n = 1), acute lymphoblastic leukemia (n = 1), and ovarian cancer (n = 3). The trial was stopped because of excess morbidity in the form of streptococcal septic shock in the group not receiving gram-positive prophylaxis. There were significantly fewer overall infections (10 versus 3; P = 0.016) and streptococcal infections (9 versus 1; P = 0.0078) in the group receiving gram-positive prophylaxis. There were no significant differences in the numbers of deaths, duration of broad-spectrum antibiotics, or incidence of neutropenic fever between the two groups. Prophylaxis for gram-positive infections with penicillin or vancomycin is effective in reducing the incidence of streptococcal infections in patients undergoing high-dose chemotherapy and autologous bone marrow transplant. However, this approach may carry a risk of fostering resistance among streptococci to penicillin or vancomycin.<\/jats:p>","DOI":"10.1128\/aac.38.3.576","type":"journal-article","created":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T00:05:50Z","timestamp":1340841950000},"page":"576-579","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":30,"title":["Randomized trial of the addition of gram-positive prophylaxis to standard antimicrobial prophylaxis for patients undergoing autologous bone marrow transplantation"],"prefix":"10.1128","volume":"38","author":[{"given":"E R","family":"Broun","sequence":"first","affiliation":[{"name":"Bone Marrow Transplant Program, Indiana University School of Medicine, Indianapolis."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J L","family":"Wheat","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplant Program, Indiana University School of Medicine, Indianapolis."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P H","family":"Kneebone","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplant Program, Indiana University School of Medicine, Indianapolis."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Sundblad","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplant Program, Indiana University School of Medicine, Indianapolis."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R A","family":"Hromas","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplant Program, Indiana University School of Medicine, Indianapolis."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Tricot","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplant Program, Indiana University School of Medicine, Indianapolis."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.38.3.576","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.38.3.576","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:37:02Z","timestamp":1645457822000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.38.3.576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,3]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1994,3]]}},"alternative-id":["10.1128\/AAC.38.3.576"],"URL":"https:\/\/doi.org\/10.1128\/aac.38.3.576","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,3]]},"assertion":[{"value":"1994-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}